SCINAI IMMUNOTHERAPEUTICS LT
SCNINASDAQ🏆 #4218 by market capUS Equity
$0.24▼ $0.01 (−3.78%)
Market closed · at close1h—
24h▼ 3.8%
7d▼ 8.8%
14d▼ 3.2%
30d▼ 3.3%
1y▼ 83.2%
🏦Market Cap
$5.01B
Small Cap
📈Revenue Growth (YoY)
+216.7%
High Growth
📊Gross Margin
-195.9%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
42
Weak
Trading Snapshot
- Day Range
- $0.24 – $0.24
- 52-Week Range
- $0.21 – $1.97
- Volume
- $1.73B
- Avg Volume
- $2.26B
- Shares Outstanding
- 20.68B
- Next Earnings
- Oct 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $697,915
- P/E Ratio
- —
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-0.00
- Dividend Yield
- —
Why Investors Own SCNI
- ✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$3M▲ +16.5% YoY
Gross Margin (TTM)
67.3%▲ +3.8% YoY
Operating Income (TTM)
$419,448▲ +16.5% YoY
Free Cash Flow (TTM)
$313,943▲ +16.5% YoY
About SCINAI IMMUNOTHERAPEUTICS LT
A company profile for SCINAI IMMUNOTHERAPEUTICS LT isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Price Target
ⓘAverage Target
$0.24
▼ −1.0% Downside
High Target$0.27
Low Target$0.18
Based on 28 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
SCINAI IMMUNOTHERAPEUTICS LT tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift SCNI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
SCINAI IMMUNOTHERAPEUTICS LT announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.